Featured Research

from universities, journals, and other organizations

Arsenic biomethylation required for oxidative DNA damage

Date:
November 23, 2009
Source:
Journal of the National Cancer Institute
Summary:
Biomethylation of arsenic compounds appears to cause oxidative DNA damage and to increase their carcinogenicity, according to a new study.

Biomethylation of arsenic compounds appears to cause oxidative DNA damage and to increase their carcinogenicity, according to a new study published online November 23 in the Journal of the National Cancer Institute.

Although biomethylation was once believed to detoxify inorganic arsenic, it is now thought to enhance its toxicity and potentially its carcinogenicity.

To assess the role of arsenic biomethylation in oxidative DNA damage in mice, Michael P. Waalkes, Ph.D., of the National Cancer Institute at the National Institute of Environmental Health Sciences, and colleagues compared oxidative DNA damage in methylation-competent cell lines vs. methylation-deficient cell lines exposed to arsenic.

Exposure of the methylation-competent cells, but not methylation-deficient cells, was followed by a sharp rise in oxidative DNA damage. Subsequent to the peak of oxidative DNA damage, methylation-competent cells, more rapidly than methylation-deficient cells, acquired the in vitro characteristics of cancer cells.

Animals have been engineered not to biomethylate arsenic. "Although inorganic arsenicals have not yet been tested for carcinogenic effects in these genetically altered mice, this clearly should be a high priority," the authors write.

In an accompanying editorial, Michael F. Hughes, Ph.D., of the Environmental Protection Agency, in Research Triangle Park, N.C., reviews the history of research concerning arsenic methylation and its role in carcinogenesis. He notes that future investigations will need to determine whether arsenic-induced oxidative stress contributes to arsenic-induced toxicity and carcinogenesis by affecting cell signaling pathways and/or apoptosis.


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Journal of the National Cancer Institute. "Arsenic biomethylation required for oxidative DNA damage." ScienceDaily. ScienceDaily, 23 November 2009. <www.sciencedaily.com/releases/2009/11/091123171238.htm>.
Journal of the National Cancer Institute. (2009, November 23). Arsenic biomethylation required for oxidative DNA damage. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/11/091123171238.htm
Journal of the National Cancer Institute. "Arsenic biomethylation required for oxidative DNA damage." ScienceDaily. www.sciencedaily.com/releases/2009/11/091123171238.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins